Trial Profile
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Fragile X Syndrome
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 22 Jan 2024
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Acronyms CONNECT-FX OLE
- Sponsors Zynerba Pharmaceuticals
- 01 May 2023 Time frame of primary endpoint has been changed from up to 1 year to up to 72 months.
- 01 May 2023 Planned End Date changed from 31 May 2027 to 31 Aug 2027.
- 01 May 2023 Planned primary completion date changed from 31 May 2027 to 31 Aug 2027.